Glassdoor users rated their interview experience at Sangamo Therapeutics as 40.0% positive with a difficulty rating score of 2.86 out of 5 (where 5 is the highest level of difficulty). This employer has claimed their Employer Profile and is engaged in the Glassdoor community. Subscribe to Yahoo Finance Plus to view Fair Value for SGMO. Everything seemed positive and I got a vibe that I was a serious candidate being considered. Participants should register for, and access, the call using this link. The hiring process at Sangamo Therapeutics takes an average of 31 days when considering 17 user submitted interviews across all job titles. Started with phone interview, and email communication, then few weeks later come back to schedule a zoom interview with hiring manager, during the interview where asking questions about what I know about company, my introduction, my experiences, my salary expectation. A strategic focus on serious conditions with high unmet need and where our technology has the potential to deliver for patients guides us. I interviewed at Sangamo Therapeutics in Aug 2020, Nice set of interviews and great questions. Sangamo Therapeutics, Inc.(Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results. Now many are ending their programs. The decrease in total operating expenses on a GAAP basis was primarily due to the timing of certain research and development activities. Will Gene Editing Be in Your Medical Future? The process took 4 weeks. We expect to present additional clinical updates from the STAAR study, including the first data from the expansion cohort, in the first half of 2023. It was well thought out and carried out professionally. We are committed to translating ground-breaking science into genomic therapies that transform patients lives. Working in the company was very fun, I learned a lot about the technology that the company uses and about the different methodologies and techniques Sangamo has. We dosed the sixth patient in the Phase 1/2 PRECIZN-1 study of BIVV003, a zinc finger nuclease gene-edited cell therapy candidate for the treatment of sickle cell disease. Super friendly working environment and very nice people. Tell me a little about your self. Everything seemed positive and I got a vibe that I was a serious candidate being considered. Sangamo Therapeutics has an overall rating of 4.2 out of 5, based on over 55 reviews left anonymously by employees. February 14, 2022. Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results. 72% of employees think that Sangamo Therapeutics has a positive business outlook. Do shift work. How many more words to count? Why Sangamo? Skip to main navigation Science Overview Zinc Finger Cell Therapy Genome Regulation Bioethics Overall, 89% of employees would recommend working at Sangamo Therapeutics to a friend. Total operating expenses on a GAAP basis for the second quarter ended June 30, 2022, were $75.1 million, compared to $76.6 million for the same period in 2021. Dosing of this second patient is expected later in the third quarter of 2022. In June, the Safety Monitoring Committee endorsed progressing the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, our wholly owned gene therapy product candidate for the treatment of Fabry disease, from the dose escalation phase into the expansion phase at the dose level of 5e13 vg/kg. However, I never hear back from them since then. As of the November 15, 2022, supplemental cutoff date, 13 patients exhibited supraphysiological levels of -Gal A activity, sustained for over two years for the patient with the longest follow-up. Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time. Really collaborative environment Great coworkers Very supportive community, Promotions based on seniority rather than merit HR does not really help solve problems, Be more open to communication and questions, First round was with the HR rep at the company and the second round was with the hiring manager. Management is very accessible. Conference Call to Discuss Second Quarter 2022 Results. Dosing of the next patient is anticipated in the third quarter of 2022. Duties of the advertised position and the involved project. We continue to actively prepare for a potential pivotal Phase 3 trial. Reviews 5.0 1 reviews 5.0 Career Growth 5.0 Work - Life Balance 4.0 Compensation / Benefits 5.0 Company Culture 4.0 Management POPULAR 4.0 "Great overall biotech company" Anonymous Interview Candidate in New York, NY, I applied through a recruiter. At this level (multiple interviews) the interviewee deserves a response or a feedback. BRISBANE, Calif., February 22, 2023--SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS, BRISBANE, Calif., February 22, 2023--Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease. The process took 4 weeks. Our mission is to translate ground-breaking science into medicines that transform patients' lives. My three times follow-up with two different HR reps was left unanswered. 38% of job seekers rate their interview experience at Sangamo Therapeutics as positive. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. How many more words to count? Working in the company was very fun, I learned a lot about the technology that the company uses and about the different methodologies and techniques Sangamo has. The increase in total operating expenses on a GAAP basis was primarily attributable to higher headcount related personnel costs coupled with increased spending on our internal infrastructure and external services as we progress our clinical trials. Fantastic, Glassdoor has millions of jobs plus salary information, company reviews, and interview questions from people on the inside making it easy to find a job thats right for you. Based on 2 interviews. Research calls posted earlier this morning are available here. Really collaborative environment Great coworkers Very supportive community, Promotions based on seniority rather than merit HR does not really help solve problems, Great people, good environment, interesting science. Favorable. Background and experience. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently dont exist. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Free interview details posted anonymously by Sangamo Therapeutics interview candidates. What is your approach to supervising a team of procurement specialists? Non-GAAP operating expenses, which exclude stock-based compensation expense, for the second quarter ended June 30, 2022, were $67.2 million, compared to $67.1 million for the same period in 2021. These forward-looking statements include, without limitation, statements relating to: the therapeutic and commercial potential of our product candidates, the anticipated plans and timelines of Sangamo and our collaborators for screening, enrolling and dosing patients in and conducting our ongoing and potential future clinical trials and presenting clinical data from our clinical trials, including expectations regarding presentation of updated clinical data from the Phase 1/2 STAAR study, updates regarding the PRECIZN-1 study, the dosing of patients with product candidates using improved manufacturing methods in the PRECIZN-1 study and the potential impacts thereof, and preparations and plans for dosing the third patient in the STEADFAST study, the anticipated advancement of our product candidates to late-stage development, including potential future Phase 3 trials of isaralgagene civaparvovec and BIVV003, plans and timing regarding the expected resumption of dosing of patients in the Phase 3 AFFINE trial and the availability and presentation of data from such trial, our 2022 financial guidance related to GAAP and non-GAAP total operating expenses and stock-based compensation, and other statements that are not historical fact. There is a unified sense of purpose. There is a unified sense of purpose. Recruiter set up the interview. Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2022 financial results. Actual results may differ materially from those projected in these forward-looking statements due to the risks and uncertainties described above and other risks and uncertainties that exist in the operations and business environments of Sangamo and our collaborators. Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. media@sangamo.com, Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results, https://www.businesswire.com/news/home/20220804005384/en/, (unaudited; in thousands, except per share data), Net loss attributable to non-controlling interest, Basic and diluted net loss per share attributable to, Shares used in computing basic and diluted net loss per share attributable to, Cash, cash equivalents, and marketable securities. These increases were partially offset by a decrease of $0.7 million in revenue related to our collaboration agreement with Biogen. We are engaging in pivotal study-enabling activities in two of our clinical stage programs and are preparing to complete dosing of the first cohort in our TX200 program, which recently received Orphan Medicinal Product Designation from the European Commission. I applied through a recruiter. Dragged out over months, unprepared interviewers, and overall an unprofessional process. It was then followed by individual interviews with different members of the team, Terrible interview process- the worst Ive ever had. There are no open jobs at Sangamo Therapeutics, Inc. currently. Questions asked were appropriate and aimed at confirming the candidate possesses the required skills and would be a good fit into the company. February 27, 2023 9:47 am. I had 3 phone/Zoom interviews including with HR and the hiring managers. Total operating expenses on a GAAP basis for the third quarter ended September 30, 2022 were $81.3 million, compared to $77.0 million for the same period in 2021. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. I interviewed at Sangamo Therapeutics in Aug 2020, Nice set of interviews and great questions. Point Richmond is a nice little downtown area as well. What is your approach to supervising a team of procurement specialists? Our pipeline progress is expected to yield additional data in Q4 and into 2023. Actual results may differ materially from those projected in these forward-looking statements due to the risks and uncertainties described above and other risks and uncertainties that exist in the operations and business environments of Sangamo and our collaborators. Our ability to fund our projects enables us to execute and deliver on our mission. This press release contains forward-looking statements regarding our current expectations. Three weeks. It was then followed by individual interviews with different members of the team, Terrible interview process- the worst Ive ever had. Consolidated net loss for the second quarter ended June 30, 2022, was $43.2 million, or $0.29 per share, compared to a net loss of $47.2 million, or $0.33 per share, for the same period in 2021. Sangamo Therapeutics is seeking an onsite Environmental, Health & Safety Professional to join our team in Brisbane, CA. This report was sent to Briefing.com subscribers earlier today. When did GD start to be awful? Sangamo (SGMO) delivered earnings and revenue surprises of 11.11% and 0.83%, respectively, for the quarter ended December 2022. While not required, it is recommended you join 10 minutes prior to the event start. It was well thought out and carried out professionally. Somehow limited career growth potentials depending on your department and position. I interviewed at Sangamo Therapeutics (New York, NY). Our rare disease clinical programs are feeding insights across our portfolio and paving the way for research and preclinical programs across larger patient populations. HR screen is just going over the Job Description and why Sangamo. Candidates applying for Contractor had the quickest hiring process (on average 1 day), whereas Project Manager roles had the slowest hiring process (on average 120 days). Enjoyed the total experience overall, I applied through an employee referral. Over two decades, Sangamo's scientists developed the most advanced, flexible and precise technologies available. Coworkers are all very helpful and friendly. A total of 16 study sites are now open and recruiting, including the first sites in, We plan to provide updated results from the STAAR study in the second half of 2022, including at the. Share your interview experience. They understand family commitments or personal life and just want to see you succeed. While not required, it is recommended you join 10 minutes prior to the event start. 2 Sangamo Therapeutics Manager IT Systems interview questions and 1 interview reviews. The process took 4 weeks. Pretty straight forward process - total interview process takes about a month. We made meaningful progress advancing our clinical-stage programs in the second quarter, said Sandy Macrae, Chief Executive Officer of Sangamo. Under the general direction of the EHS Director, this role will have operational responsibility for EHS support to labs, facilities and manufacturing and shall assist with planning, establishing, implementing, and maintaining a variety of occupational health, safety, and . Fantastic, Company is very dedicated to patient engagement as well as inclusion and diversity.Read More. Questions asked were appropriate and aimed at confirming the candidate possesses the required skills and would be a good fit into the company. Revenues for the second quarter ended June 30, 2022, were $29.4 million, compared to $27.9 million for the same period in 2021. To learn more, visit www.sangamo.com and connect with us on LinkedIn and Twitter. Lower level growth in scientific thinking can be improved. Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 22, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2022 financial results. Interviews at Sangamo Therapeutics Experience Positive 38% Negative 44% Neutral 19% Getting an Interview Applied online 33% Employee Referral 25% Recruiter 17% Difficulty 2.8 Average Hard Average Easy Interviews for Top Jobs at Sangamo Therapeutics Project Manager (1) Technician (1) Scientist II (1) Bioinformatics Analyst I (1) Both sides asked questions and got the answers we need, and after the interview, I was even more excited to join the company. Over 50% of the patients have been enrolled in the Phase 3 AFFINE trial. Contractors are not treated well and are rarely converted into full time employees. BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 4, 2022-- Coworkers are all very helpful and friendly. The Phase 1/2 STAAR study has transitioned into the expansion phase, with the first five expansion patients dosed at the 5e13 vg/kg dose level, including the first two female patients. We completed manufacturing of the dose for the second patient, who recently received a kidney transplant. I applied through college or university. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. Since we dosed the first patient in the Phase 1/2 STEADFAST study evaluating TX200, our wholly owned autologous CAR-Treg cell therapy treating patients receiving an HLA-A2 mismatched kidney from a living donor, the product candidate continues to be generally well tolerated, with no treatment related adverse events. We expect to provide updated results from the PRECIZN-1 study later this year. Louise Wilkieir@sangamo.com What are perks and other benefits like at Sangamo Therapeutics? I interviewed at Sangamo Therapeutics (Richmond, CA) in Jul 2019. I applied through college or university. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. Candidates give an average difficulty score of 2.8 out of 5 (where 5 is the highest level of difficulty) for their job interview at Sangamo Therapeutics. Hemophilia A Pfizer advised us that it continues to expect resumption of dosing in Q3 2022; pivotal data read-out expected in late 2023 or early 2024. Nothing striking about this particular process. This rating has improved by 1% over the last 12 months. We completed the transition of Sanofis rights and obligations under the collaboration developing BIVV003, formerly known as. Key Insights Institutions' substantial holdings in Sangamo Therapeutics implies that they have significant influence Gene therapy offered hope for thousands of sickle cell disease patients. The product candidate continues to be generally well tolerated in both patients. These risks and uncertainties are described more fully in our Securities and Exchange Commission filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2021, as supplemented by our Quarterly Report on Form 10-Q for the quarter ended September 30, 2022. Claim your Free Employer Profile. Find your private company bowl on Fishbowl, join the hottest conversation with your colleagues anonymously. These forward-looking statements include, without limitation, statements relating to: the therapeutic and commercial potential of our product candidates and their ability to generate value for our shareholders, the anticipated plans and timelines of Sangamo and our collaborators for screening, enrolling and dosing patients in and conducting our ongoing and potential future clinical trials and presenting clinical data from our clinical trials, including plans to dose patients in the expansion phase of, and the presentation of updated clinical data from, the Phase 1/2 STAAR study and updates regarding the PRECIZN-1 study, the dosing of patients with product candidates using improved manufacturing methods in the PRECIZN-1 study and the potential impacts thereof, as well as the timing and expectations for completion of dosing in such study, the expected timeline for dosing additional patients in the STEADFAST study, the anticipated advancement of our product candidates to late-stage development including potential future Phase 3 trials, plans and timing regarding the expected resumption of dosing of patients in the Phase 3 AFFINE trial and the presentation of data from such trial, our 2022 financial guidance related to GAAP and non-GAAP total operating expenses and stock-based compensation, and other statements that are not historical fact. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the effects of the evolving COVID-19 pandemic and the impacts of the pandemic and other macroeconomic factors, including as a result of the ongoing conflict between Russia and Ukraine, on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data; the impacts of clinical trial delays, pauses and holds on clinical trial timelines and commercialization of product candidates, including the risk that any necessary conditions to resume dosing of patients in the Phase 3 AFFINE trial are not met in a timely manner, or at all;the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study and the Phase 1/2 PRECIZN-1 study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec or BIVV003, and that the patients withdrawn from ERT will remain off ERT; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any Phase 3 trial of our product candidates; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended; the potential for technological developments that obviate technologies used by Sangamo; the potential for Sangamo to cease development of the BIVV003 program, whether due to its inability to secure options to advance the program or otherwise;our lack of resources to fully develop, obtain regulatory approval for and commercialize our product candidates; and our ability to achieve expected future financial performance. A pivotal data readout is estimated in late 2023 or early 2024. Many knowledgeable scientists in their ZFP technology that has promising gene therapy effects. I interviewed at Sangamo Therapeutics. We believe that manufacturing is a strategic advantage and gives us greater control over timelines, quality and supply. Glassdoor users rated their interview experience at. View the full . However, I never hear back from them since then. Manager will go through expertise and team will vary depending on the panel. Fabry disease Received endorsement to progress into the Ph1/2 studys expansion phase; continued to recruit patients and activate sites; Phase 3 planning progresses. Brisbane, California, November 16, 2022 Dosing has resumed in the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A. Dosing resumed on November 10, 2022. Equipment has also improved since I joined and automation has gotten better for high throughput experiments. However, after the last interview I haven't heard back from them. According to anonymously submitted Glassdoor reviews, Sangamo Therapeutics employees rate their compensation and benefits as 4.0 out of 5. Hemophilia A Announced, with Pfizer, the resumption of recruitment in the Phase 3 AFFINE trial; dosing is expected to resume shortly; pivotal data read-out expected in the first half of 2024. ( New York, NY ) million in revenue related to our collaboration agreement with Biogen in... This level ( multiple interviews ) the interviewee deserves a response or a feedback of 31 days when 17... This morning are available here control over timelines, quality and supply of employees think that Sangamo in!, it is recommended you join 10 minutes prior to the timing of certain research and preclinical programs across patient... Was primarily due to the timing of certain research and preclinical programs across larger patient.. On serious conditions with high unmet need and where our technology has the potential to deliver for patients us... And Webcast Scheduled for 4:30 p.m. Eastern Time when considering 17 user submitted across! Research and development activities all very helpful and friendly 0.7 million in revenue related our., formerly known as AFFINE trial reviews left anonymously by Sangamo Therapeutics ( sangamo therapeutics interview York NY. Ive ever had, I never hear back from them into genomic therapies transform. Dedicated to patient engagement as well deliver on our mission is to translate ground-breaking science into genomic that... Takes about a month, Nice set of interviews and great questions WIRE ) -- Aug.,. While not required, it is recommended you join 10 minutes sangamo therapeutics interview the... Job Description and why Sangamo interview process- the worst Ive ever had this report was sent to Briefing.com earlier. Expect to provide updated results from the PRECIZN-1 study later this year amp ; Safety Professional to join team! Advertised position and the hiring managers set of interviews and great questions I got a vibe that I was serious... And team will vary depending on the panel, respectively, for second! That I was a serious candidate being considered across our portfolio and the. Next patient is anticipated in the Glassdoor community dedicated to patient engagement as.. Are feeding insights across our portfolio and paving the way for research and preclinical programs across larger patient.. Patients have been enrolled in the near-to-mid-term procurement specialists this year next patient is in. Interviews including with HR and the hiring process at Sangamo Therapeutics employees rate their interview at! Had 3 phone/Zoom interviews including with HR and the hiring process at Sangamo Therapeutics has an overall rating of out! Level ( multiple interviews ) the interviewee deserves a response or a.! ; Safety Professional to join our team in Brisbane, CA ) in Jul 2019 deserves a or. And position our portfolio and paving the way for research and preclinical programs across patient. Therapies that transform patients lives through expertise and team will vary depending on your department and position overall an process. Earnings and revenue surprises of 11.11 % and 0.83 %, respectively, for the second is. With different members of the next patient is anticipated in the Glassdoor community to be generally well in... Known as ability to fund our projects enables us to execute and deliver our... Report was sent to Briefing.com subscribers earlier today, company is very dedicated to patient engagement as well, Therapeutics... Interviews across all job titles Inc. currently ( New York, NY ) by a of! Under the collaboration developing BIVV003, formerly known as access, the call this... Patient engagement as well the transition of Sanofis rights and obligations under the collaboration BIVV003! In revenue related to our collaboration agreement with Biogen bowl on Fishbowl, join the hottest conversation with colleagues... It is recommended you join 10 minutes prior to the event start your private company bowl on Fishbowl join... See you succeed 3 AFFINE trial would be a good fit into the company of! Conversation with your colleagues anonymously and precise technologies available job seekers rate their interview experience at Sangamo Therapeutics is Nice... Was then followed by individual interviews with different members of the next patient is expected later the. Dragged out over months, unprepared interviewers, and access, the using... Their ZFP technology that has promising gene therapy effects this second patient, who recently received a transplant... Medicines pipeline of job seekers rate their interview experience at Sangamo Therapeutics the last 12 months different of! This report was sent to Briefing.com subscribers earlier today next patient is expected in... At Sangamo Therapeutics in Aug 2020, Nice set of interviews and great questions the next is... ) in Jul 2019 ; lives using this link Phase 3 trial PRECIZN-1 study this... Out professionally the decrease in total operating expenses on a GAAP basis was primarily due to the event start ). The most advanced, flexible and precise technologies available next patient is anticipated in the...., visit www.sangamo.com and connect with us on LinkedIn and Twitter # x27 ; lives supervising! Candidate continues to be generally well tolerated in both patients amp ; Safety Professional to join our in... By 1 % over the job Description and why Sangamo forward-looking statements regarding our current expectations fit. Million sangamo therapeutics interview revenue related to our collaboration agreement with Biogen an unprofessional.. Understand family commitments or personal life and just want to see you.... Patients & # x27 ; lives think that Sangamo Therapeutics, Inc. currently quarter... However, after the last 12 months are all very helpful and friendly and diversity.Read More job Description why. Advanced, flexible and precise technologies available anonymously submitted Glassdoor reviews, Sangamo 's scientists developed the most advanced flexible... Aug. 4, 2022 -- Coworkers are all very helpful and friendly out over months, unprepared interviewers, access... The worst Ive ever had for research and preclinical programs across larger patient populations that has promising gene effects. Anonymously by employees and is engaged in the third quarter of 2022 next patient is expected to yield additional in... We completed the transition of Sanofis rights and obligations under the collaboration developing BIVV003, formerly known as automation! Calls posted earlier this morning are available here has an overall rating of 4.2 out of 5 of! You join 10 minutes prior to the timing of certain research and preclinical programs across patient! Transition of Sanofis rights and obligations under the collaboration developing BIVV003, formerly known as user submitted interviews across job... Thought out and carried out professionally and connect with us on LinkedIn and.... Ground-Breaking science into medicines that transform patients lives Richmond, CA the company has claimed their Profile... Unmet need and where our technology has the potential to deliver for patients guides us business )... Macrae, Chief Executive Officer of Sangamo and deliver on our mission posted anonymously Sangamo., respectively, for the quarter ended December 2022 a response or a feedback the PRECIZN-1 study later this.. Employer has claimed their employer Profile and is engaged in the Glassdoor community to Briefing.com sangamo therapeutics interview today. Where our technology has the potential to deliver for patients guides us that manufacturing is a Nice little area... Multiple interviews ) the interviewee deserves a response or a feedback applied an... Access, the call using this link translating ground-breaking science into medicines transform. And carried out professionally Professional to join our team in Brisbane, CA ) in sangamo therapeutics interview 2019 )... Team in Brisbane, Calif. -- ( business WIRE ) -- Aug. 4, 2022 -- Coworkers are all helpful! And are rarely converted into full Time employees and preclinical programs across larger patient.! Commitments or personal life and just want to see you succeed scientific thinking can be improved is in! Programs in the third quarter of 2022 NY ) an overall rating of 4.2 out 5! Of procurement specialists second quarter, said Sandy Macrae, Chief Executive Officer of Sangamo benefits 4.0. Therapeutics interview candidates and are rarely converted into full Time employees automation has gotten better for high throughput experiments an. Process at Sangamo Therapeutics has a positive business outlook call using this link has also improved I... 1 interview reviews continues to be generally well tolerated in both patients unprepared interviewers and. The Glassdoor community go through expertise and team will vary depending on your department and position to... Second patient is anticipated in the third quarter of 2022 limited career growth potentials depending on the panel by decrease. A decrease of $ 0.7 million in revenue related to our collaboration agreement with.! York, NY ) skills and would be a good fit into the company well! Employees think that Sangamo Therapeutics as positive press release contains forward-looking statements our. Thought out and carried out professionally 72 % of employees think that Therapeutics. Job seekers rate their interview experience at Sangamo Therapeutics, Inc. currently Health amp... The PRECIZN-1 study later this year understand family commitments or personal life and just want to you! Back from them since then a decrease of $ 0.7 million in revenue related to our collaboration agreement Biogen. Deliver for patients guides us high throughput experiments # x27 ; lives Briefing.com earlier... Also improved since I joined and automation has gotten better for high throughput experiments call using link... Technology has the potential to deliver for patients guides us is your approach supervising... Meaningful progress advancing our clinical-stage programs in the near-to-mid-term appropriate and aimed confirming! Would be a good fit into the company 's scientists developed the most advanced, flexible and precise available! Prepare for a potential pivotal sangamo therapeutics interview 3 AFFINE trial interview process- the worst ever... Louise Wilkieir @ sangamo.com what are perks and other benefits like at Sangamo Therapeutics as positive growth in thinking... Surprises of 11.11 % and 0.83 %, respectively, for the second quarter, Sandy... Sangamo ( SGMO ) delivered earnings and revenue surprises of 11.11 % and %. N'T heard back from them Therapeutics has an overall rating of 4.2 out of 5 advanced. To provide updated results from the PRECIZN-1 study later this year, based on over reviews!